

Form 51-102F3

MATERIAL CHANGE REPORT UNDER 7.1(1) OF NATIONAL INSTRUMENT 51-102

ITEM 1 NAME AND ADDRESS OF COMPANY

Biosenta Inc.
1120 Finch Avenue West, Suite 503
Toronto, Ontario M3J 3H7

ITEM 2 DATE OF MATERIAL CHANGE

May 15, 2013

ITEM 3 NEWS RELEASE

A news release announcing the material change was issued by the Company on May 15, 2013 through Newsfile.

ITEM 4 SUMMARY OF MATERIAL CHANGE

See the press release issued May 15, 2013 attached as Schedule "A" hereto.

ITEM 5 FULL DESCRIPTION OF MATERIAL CHANGE

See the press release issued May 15, 2013 attached as Schedule "A" hereto.

ITEM 6 RELIANCE ON SUBSECTION 7.1 (2) OF NATIONAL INSTRUMENT 51-102

This report is not being filed on a confidential basis.

ITEM 7 OMITTED INFORMATION

Not applicable.

ITEM 8 EXECUTIVE OFFICER

The following officer is knowledgeable about the material change and this report:
Bruce Lewis
Secretary
416 410 2019

ITEM 9 DATE OF REPORT

DATED in the Province of Ontario, this 15th day of May, 2013.

Schedule "A"

BIOSENTA EXECUTIVE OFFICER APPOINTMENTS

Toronto, Ontario, May 15, 2013 – Biosenta Inc. (CNSX: ZRO) (the “Company”) today announced that Bruce Lewis, the Chairman and Chief Executive Officer, President and Secretary of the Company resigned effective immediately as the Chief Executive Officer and President of the Company. Mr. Lewis will be continuing an executive role as the Secretary of the Company and Chairman of the Board of Directors. The Company wishes to extend its gratitude to Mr. Lewis for steering the Company through the early stages of its development of its anti-microbial line of business.

The Company is pleased to announce the appointment of Mr. Edward Pardiak as its new President and Chief Executive Officer and Mr. Marcus Martin as its Chief Technology Officer. Mr. Pardiak and Mr. Martin have been a directors of the Company since February 2011 and are each co-licensors and principals of a co-licensor of certain intellectual property rights held by the Company.

About Biosenta Inc.

Biosenta Inc.’s line of retail anti-microbial products will effectively kill mould, bacteria and fungi on contact and prevent re-growth. These products address the demand created by the mounting health and environmental concerns. Mould can affect the immune system, nervous system, liver, kidneys, blood and cause brain damage.

Biosenta will also manufacture and distribute an anti-microbial filler. Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attracting mould. Annual global revenue in the calcium carbonate filler industry approximates 140 billion dollars. Biosenta will produce anti-microbial filler that performs 'filling' and 'bulking' functions like calcium carbonate. Biosenta’s filler product will not attract moisture and consequently mould infestation. Biosenta’s filler with its anti-microbial high ph core in individual particles will enhance commercial product life and eradicate a broad spectrum of known bacteria, fungi, algae and other micro-organisms by suppression of their reproduction.

On behalf of the Board of Directors of Biosenta Inc.

Bruce Lewis
Chairman

The CNSX has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release. Neither the CNSX nor its Regulation Services Provider (as such term is defined in the policies of the CNSX) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:
Edward Pardiak, President & Chief Executive Officer
Biosenta Inc.
1120 Finch Avenue West, Suite 503,
Toronto, Ontario M3J 3H7
(416) 410 2019

Investor Relations contact:
Investor Cubed Inc.
Neil Simon
647-258-3311
888-258-3323
info@investor3.ca